Betahistin-SZ, tablets 16 mg 60 pcs

Pharmacotherapeutic group:

Histamine drug.

ATC code: [N07CA01].

Pharmacodynamics:

Betahistine acts mainly on histamine H1- and H3-receptors of the inner ear and vestibular nuclei of the CNS. By means of direct agonist effect on H1-receptors of the inner ear vessels and indirectly through the effect on H3-receptors it improves microcirculation and capillary permeability, normalizes the endolymph pressure in the cochlea and labyrinth. At the same time betahistine increases blood flow in the basilar artery.

It has a pronounced central effect, being an inhibitor of H3-receptor nuclei of the vestibular nerve. It improves conductivity in neurons of vestibular nuclei at brain stem level. Clinical manifestation of the above properties is reduction of frequency and intensity of dizziness, decrease of tinnitus, improvement of hearing in case of its decrease.

Pharmacokinetics:

Absorbed quickly, binding to plasma proteins is low. Maximum concentration in plasma after 3 hours. The elimination half-life is in 3-4 hours. It is almost completely excreted by the kidneys as a metabolite (2-peridylacetic acid) within 24 hours.

Indications

Active ingredient

Composition

Active ingredient is betahistine dihydrochloride.

Auxiliary substances:

cellulose microcrystalline;

p> lactose (milk sugar);

citric acid;

Colloidal silicon dioxide (aerosil);

talc;

magnesium stearate;

sodium lauryl sulfate;

Starch 1500 (pregelatinized starch).

Description:

The tablets 16 mg are white or almost white, flat-cylindrical in color, with a bevel and a rib.

How to take, the dosage

Internal, with meals. 1/2-1 tablets 3 times a day.

Improvement is usually noticed at the beginning of therapy.

Stable therapeutic effect occurs after two weeks of treatment and can build up over several months of treatment.

The treatment is long. The duration of the drug is chosen individually.

Interaction

Special Instructions

Contraindications

– hypersensitivity to any of the components of the drug, children under 18 years of age (due to lack of data), pregnancy and lactation (due to lack of data);

With caution: peptic ulcer or duodenal ulcer (including anamnesis), pheochromocytoma, bronchial asthma. These patients should be regularly monitored during the treatment period;

– pregnancy and lactation.

There is not enough data to assess the effect of the drug during pregnancy and lactation. In this regard it is not recommended to use during pregnancy. Breast-feeding should be stopped for the period of treatment.

Side effects

Overdose

Symptoms: nausea, vomiting, seizures.

Treatment: gastric lavage, administration of activated charcoal, symptomatic therapy.

Similarities